Landiolol, an ultra-short-acting β?-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).

Tatsuo Iwasaki

Landiolol, an ultra-short-acting β?-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).

University Hospital

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	1097-1101
Number of pages	5
Journal	Circ J
Volume	76
Publication status	Published - 2012

Cite this

Iwasaki, T. (2012). Landiolol, an ultra-short-acting β?-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J, 76, 1097-1101.

@article{0298237c6ceb4699b904da15fded35e3,

title = "Landiolol, an ultra-short-acting β?-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).",

author = "Tatsuo Iwasaki",

year = "2012",

language = "English",

volume = "76",

pages = "1097--1101",

journal = "Circ J",

}